A Comprehensive Systematic Review Comparing Nutraceutical Supplementation (Magnesium, Chromium, Coenzyme Q10, Astaxanthin and Related Agents) on the Lipid Profile, HbA1c and HOMA-IR in Patients with Type 2 Diabetes Mellitus and Dyslipidaemia
The Indonesian Journal of General Medicine · 2026
DOI: 10.70070/3693z815 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Indonesian Journal of General Medicine, 2026. Verfasst von Ade Dwirisha Putra und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Type 2 diabetes mellitus (T2DM) and atherogenic dyslipidaemia coexist in the majority of patients with cardiometabolic disease, and residual dyslipidaemic and insulin-resistant risk persists in a substantial proportion of patients despite optimal statin and glucose-lowering therapy. Nutraceutical supplementation—most prominently magnesium, chromium, coenzyme Q10 (CoQ10) and astaxanthin—has been proposed as an adjunctive strategy acting on mitochondrial bioenergetics, insulin-receptor signalling, lipid peroxidation and adipokine biology. The evidence base, however, is fragmented into single-agent trials that have never been compared within one analytical framework, and the dose-response architecture of these agents is poorly characterised in clinical practice.
Methods
A comprehensive systematic review was conducted in accordance with PRISMA 2020. Eligible designs were RCTs, cohort, case-control, cross-sectional, and other observational studies; systematic reviews and meta-analyses were excluded from characteristics tables but retained for corroboration. Risk of bias was appraised with RoB 2 and Newcastle-Ottawa Scale; certainty rated with GRADE. Structured narrative synthesis with vote-counting and explicit dose-response analysis was performed.
Results
Thirty-two primary studies (≥1,700 participants) met inclusion criteria, together with 16 systematic reviews/meta-analyses for corroboration. Fifteen outcome domains were analysed. Statistically significant improvements were demonstrated for all three co-primary endpoints. Magnesium 250-400 mg/day of elemental Mg significantly reduced HOMA-IR (3.8±1.1 versus 5.0±1.3, P=0.005) and HbA1c (P=0.04) in hypomagnesaemic T2DM patients. Chromium produced pooled reductions in fasting plasma glucose of 19.00 mg/dL (95% CI -36.15 to -1.85), HbA1c of 0.71% (-1.19 to -0.23) and HOMA-IR of 1.53 (-2.35 to -0.72). CoQ10 significantly reduced HbA1c by 0.37±0.17% (P=0.032) and, at 120 mg/day for 24 weeks, lowered triglycerides (P=0.020), LDL-cholesterol (P=0.016) and HOMA-IR (P=0.009). Astaxanthin 12 mg/day lowered LDL-cholesterol by 0.33±0.11 mmol/L and total cholesterol by 0.30±0.14 mmol/L (both P
Zitieren
APA
Putra, A. D., Dewi, D. A. L., & Wiriantono, H. (2026). A Comprehensive Systematic Review Comparing Nutraceutical Supplementation (Magnesium, Chromium, Coenzyme Q10, Astaxanthin and Related Agents) on the Lipid Profile, HbA1c and HOMA-IR in Patients with Type 2 Diabetes Mellitus and Dyslipidaemia. The Indonesian Journal of General Medicine. https://doi.org/10.70070/3693z815
Vancouver
Putra AD, Dewi DAL, Wiriantono H. A Comprehensive Systematic Review Comparing Nutraceutical Supplementation (Magnesium, Chromium, Coenzyme Q10, Astaxanthin and Related Agents) on the Lipid Profile, HbA1c and HOMA-IR in Patients with Type 2 Diabetes Mellitus and Dyslipidaemia. The Indonesian Journal of General Medicine. 2026. doi:10.70070/3693z815
BibTeX
@article{Putra2026,
author = {Putra, Ade Dwirisha and Dewi, Dewa Ayu Liona and Wiriantono, Hidayat},
title = {A Comprehensive Systematic Review Comparing Nutraceutical Supplementation (Magnesium, Chromium, Coenzyme Q10, Astaxanthin and Related Agents) on the Lipid Profile, HbA1c and HOMA-IR in Patients with Type 2 Diabetes Mellitus and Dyslipidaemia},
journal = {The Indonesian Journal of General Medicine},
year = {2026},
doi = {10.70070/3693z815}
}
EUVIMED